SLGL vs SKIN

For growth investors, Sol-Gel Technologies Ltd.

(SLGL) is the stronger pick with 68. 0% revenue growth year-over-year, versus -10. 0% for The Beauty Health Company (SKIN). Analysts rate Sol-Gel Technologies Ltd. (SLGL) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Sol-Gel Technologies Ltd.

(SLGL) delivered a total return of -27. 1%, compared to -95. 3% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: SLGL returned -48. 0% versus SKIN's -94. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Sol-Gel Technologies Ltd.

(SLGL) is the lower-risk stock at 0. 09β versus The Beauty Health Company's 1. 71β — meaning SKIN is approximately 1863% more volatile than SLGL relative to the S&P 500. On balance sheet safety, Sol-Gel Technologies Ltd. (SLGL) carries a lower debt/equity ratio of 4% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Sol-Gel Technologies Ltd.

(SLGL) is pulling ahead at 68. 0% versus -10. 0% for The Beauty Health Company (SKIN). On earnings-per-share growth, the picture is similar: The Beauty Health Company grew EPS 55. 6% year-over-year, compared to -478. 9% for Sol-Gel Technologies Ltd.. Over a 3-year CAGR, SLGL leads at 70. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Beauty Health Company (SKIN) is the more profitable company, earning -3.

2% net margin versus -31. 6% for Sol-Gel Technologies Ltd. — meaning it keeps -3. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SKIN leads at -6. 9% versus -39. 2% for SLGL. At the gross margin level — before operating expenses — SLGL leads at 99. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Sol-Gel Technologies Ltd.

(SLGL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 09)). The Beauty Health Company (SKIN) carries a higher beta of 1. 71 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SLGL: -48. 0%, SKIN: -94. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SLGL (Healthcare) and SKIN (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SLGL is a small-cap high-growth stock; SKIN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.